Cargando…
Identification of drugs associated with reduced severity of COVID-19 – a case-control study in a large population
BACKGROUND: Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether existing medications have a protective effect against severe disease. Toward this objective, we conducted a large population study in...
Autores principales: | Israel, Ariel, Schäffer, Alejandro A, Cicurel, Assi, Cheng, Kuoyuan, Sinha, Sanju, Schiff, Eyal, Feldhamer, Ilan, Tal, Ameer, Lavie, Gil, Ruppin, Eytan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321549/ https://www.ncbi.nlm.nih.gov/pubmed/34313216 http://dx.doi.org/10.7554/eLife.68165 |
Ejemplares similares
-
Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population
por: Israel, Ariel, et al.
Publicado: (2021) -
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression
por: Sinha, Sanju, et al.
Publicado: (2020) -
Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection and COVID-19 severity: a retrospective case–control study
por: Israel, Ariel, et al.
Publicado: (2022) -
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
por: Israel, Ariel, et al.
Publicado: (2021) -
Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
por: Israel, Ariel, et al.
Publicado: (2021)